Subcutaneous Tarlatamab Shows Low Toxicity in Phase 1b Clinical Trial for Lung Cancer

Recent medical news highlights that subcutaneous tarlatamab demonstrated low toxicity rates in a phase 1b clinical trial. This finding is particularly relevant for patients with relapsed small cell lung cancer, as a related phase 2 study also indicated flexible dosing options for the drug, suggesting potential advancements in treatment approaches.